TP53 Modifier Impresses in Early MDS/AML Study

(MedPage Today) -- A drug that targets a common mutation in myelodysplastic syndromes (MDS) led to historically high response rates as initial treatment for MDS and acute myeloid leukemia (AML), a small clinical trial showed.
Overall, 71% of patients...